TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01320657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket
Description: Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket
Description: Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket
Description: Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks.
Study: NCT04128319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-Guard
Description: Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days (no less than 40 hours) apart. Each dose consists of 4 mg/m\^2 Body Surface Area (BSA).
Study: NCT02615210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOC-directed biopsies using the SpyGlass System
Description: The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
Study: NCT01673555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863
Study: NCT05468060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control
Study: NCT01673555

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00951379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00976937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pen auto-injector

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Administered orally once a day in the morning with or without food at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Placebo
Description: Administered orally once a day in the morning with or without food at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
Study: NCT03359889

Intervention type: DRUG
Intervention: PraxbindTM
Description: Drug
Study: NCT01281163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01199575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT02418533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menotropin
Description: Menopur is used for controlled ovarian stimulation (COH)
Study: NCT00513526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: week 0, 8, 24, 128
Study: NCT01892553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~* Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~* Cathodal tDCS: Intensity of 1.25 mA during 15 min~* Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~* Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~* Cathodal tDCS: Intensity of 1.25 mA during 15 min~* Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)
Study: NCT02725086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucostim®
Study: NCT05468060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: Placebo as control
Study: NCT02418533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recominant Follicle Stimulating Hormone (rFSH)
Description: Gonal-f is used for controlled ovarian stimulation (COH)
Study: NCT03299738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR011
Description: Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
Study: NCT04385147

Intervention type: OTHER
Intervention: Endoscopic management according to standard of care
Description: Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case

Intervention type: OTHER
Intervention: Endoscopic management according to standard of care
Description: Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
Study: NCT01053117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized approach to convert dialysis catheter to fistula
Description: This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
Study: NCT01547468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Catheterization
Description: A femoral nerve catheter will be placed prior to surgery in this group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Opioids
Description: Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
Study: NCT01999179

Intervention type: DRUG
Group type: OTHER
Intervention: Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Description: Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
Study: NCT03888859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET1402L1-ARTEMIS™ T cells -IV
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET1402L1-ARTEMIS™ T cells -intra-hepatic artery
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET1402L1-ARTEMIS™ T cells -Intratumoral Injections
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
Study: NCT05123898

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Soft tissue augmentation
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly
Study: NCT02725086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucostim®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen®
Study: NCT01199250

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02701413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApexM (Stimulation) Device
Description: Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
Study: NCT02725086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen®
Study: NCT00711217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food
Description: twice daily
Study: NCT02276521

Intervention type: BIOLOGICAL
Intervention: Cervarix®
Description: All groups will received one dose of Cervarix® vaccine

Intervention type: BIOLOGICAL
Intervention: Cervarix®
Description: All groups will received one dose of Cervarix® vaccine
Study: NCT00711217

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drink mix calorically similar to experimental product
Description: twice daily
Study: NCT00664404

Intervention type: OTHER
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
Study: NCT04152317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 200mcg Tab
Description: In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 800mcg Tab
Description: In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
Study: NCT02711059

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: parathyroidectomy
Description: surgical treatment of hyperparathyroidism
Study: NCT00969137

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intravenous saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Intravenous nicotine
Study: NCT04429685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (placebo)
Description: Saline (placebo)
Study: NCT02526758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Study: NCT00467025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
Study: NCT03339258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin Mesylate, Extended Release
Description: Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, or inactive pill.
Study: NCT02793154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)
Study: NCT02701413

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
Study: NCT00845234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
Study: NCT00467025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg PO BID
Study: NCT02793154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
Study: NCT04732338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy
Description: Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic practitioners use a wide variety of therapeutic manual techniques to improve physiological function and help restore homeostasis in the body. There is a structural assessment is to identify possible abnormalities of tissue texture. Areas of asymmetry and misalignment of bony landmarks are also evaluated, along with the quality of motion, balance, and organization. These asymmetries, also known as somatic dysfunctions, are then treated by a variety of manual treatments, administered by osteopaths.
Study: NCT00467025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 placebo IV
Description: AMG 386 placebo IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386 placebo IV
Description: AMG 386 placebo IV
Study: NCT00003225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles
Study: NCT01889654

Intervention type: OTHER
Intervention: Venous blood sampling

Intervention type: OTHER
Intervention: Venous blood sampling
Study: NCT01927419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching nivolumab
Study: NCT01764256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 subunit rotavirus vaccine
Description: P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 subunit rotavirus vaccine
Description: P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P2-VP8 subunit rotavirus vaccine
Description: P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.